Table 2 Biochemical characteristics in nephrotic patients treated with direct oral anticoagulant
Biochemical characteristics | All patients (N = 21) | Patients with no bleeding episodes (N = 16) | Patients with bleeding episodes (N = 5) |
|---|---|---|---|
eGFR (mL/min/1.73m2) | |||
DOAC start (median, (IQR)) | 85 (78–97) | 83 (76–95) | 96 (83–105) |
DOAC end (median, (IQR)) | 69 (49–101) | 71 (38–107) | 69 (60–74) |
Plasma albumin (g/L) | |||
DOAC start (median, (IQR)) | 16 (14–18) | 15 (14–18) | 17 (16–18) |
DOAC end (median, (IQR)) | 25 (21–27) | 25 (21–27) | 25 (24–36) |
Urine albumin creatinine ratio (mg/g) | |||
DOAC start (median, (IQR)) | 5268 (3219–7799) | 5484 (3960–7939) | 2236 (1985–6949) |
DOAC end (median, (IQR)) | 3104 (1882–4739) | 3545 (1912–4151) | 2080 (26–4722) |
Hemoglobin (mmol/L, median (IQR)) | 8.5 (7.9–9.0) | 8.6 (7.9–8.9) | 8.0 (7.9–10.1) |
Platelet count (10^9/L, median (IQR)) | 272 (244–338) | 315 (263–338) | 259 (244–260) |